NOVO

Human Monocomponent Insulin for the doctors and nurses of tomorrow

Insulin treatment today may lead to antibody problems in the future, a persuasive argument in favour of using the least immunogenic insulin.

Novo's human insulin is identical to the hormone they are unable to make for themselves.

There are three U100 formulations, Human Actrapid, Human Monotard and Human Protaphane all made to the same exacting standard of Monocomponent purity.

As a result of their structure and purity, Novo Human Monocomponent insulins have been shown to cause fewer antibodies than even the purest animal insulins.[1]



Prescribing Information
Human Actrapid® 100 i.u./ml ▼
Human Insulin (emp) (Neutral Insulin Injection)
Human Monotard® 100 i.u./ml ▼
Human Insulin (emp) (Insulin Zinc Suspension)
Human Protaphane® 100 i.u./ml ▼
Human Insulin (emp) (Isophane Insulin Injection)
Indications The treatment of insulin-requiring diabetic patients.
Human Actrapid is indicated for diabetics who require a quick and intense-acting insulin, particularly in emergencies such as diabetic hyperglycaemic coma, during surgery and severe infections in diabetics, and in the management of pregnant diabetics. Human Monocomponent insulin may be advantageous in the treatment of insulin-induced fat atrophy, insulin allergy, insulin resistance and when intermittent short-term therapy is required.
Dosage and Administration The dosage of Human Actrapid, Human Monotard and Human Protaphane is determined by the physician according to the needs of the patient.
Human Actrapid may be given by injection or infusion, subcutaneously, intramuscularly or intravenously. Human Monotard and Human Protaphane should be well shaken and given immediately by subcutaneous or intramuscular injection. They may be given twice, or occasionally once daily. Human Actrapid may be admixed with Human Monotard or Human Protaphane in the syringe and injected immediately. U100 insulins must only be used with U100 syringes. Peristaltic pumps (roller pumps) are not suitable for use with Human Actrapid due to the risk of precipitation. Human Monotard and Human Protaphane must not be used in insulin infusion pumps.
Contra-Indications, Warnings and Adverse Effects Insulin is contra-indicated in hypoglycaemia. In the event of an overdose, glucose should be given orally if the patient is conscious. The unconscious patient should be treated with glucose intravenously and glucagon may be administered intramuscularly or subcutaneously. On transfer from porcine monocomponent insulins or other highly purified porcine insulins to Human Monocomponent insulin, no change in dosage is anticipated other than the routine adjustments made in order to maintain stable diabetic control. However, patients transferred from conventional (predominantly bovine) insulins may require a dosage adjustment. The addition of corticosteroids, oral contraceptives or thyroid hormone replacement therapy is likely to lead to an increase in insulin requirements. The addition of a beta-adrenergic blocking agent or a monoamine oxidase inhibitor (MAOI) may also necessitate an adjustment of insulin dosage. Lipodystrophy, insulin resistance and hypersensitivity reactions have been associated with insulin therapy, but the incidence and severity of these unwanted effects is minimal with Human Monocomponent insulins. Severe local or generalised allergic reactions require immediate treatment and, in some cases, desensitisation may also be necessary.
Pack Sizes and Basic NHS Price (UK only)
All Human Monocomponent insulins
10ml vials £7.88
Product Licence Numbers
Human Actrapid 100i.u./ml 4668/0003
Human Monotard 100i.u./ml 4668/0006
Human Protaphane 100i.u./ml 4668/0007
Product Licence Holder:
Novo Industri A/S, Novo Alle, DK-2880 Bagsvaerd, Copenhagen, DENMARK.
Sole Distributor:
Farillon Ltd., Bryant Avenue, Romford, Essex RM3 0PJ. Tel: Ingrebourne 71136
References
1. Schernthaner G, et al, Immunogenicity of Human Insulin (Novo) or Pork Monocomponent Insulin in HLA-DR Typed Insulin-dependent Diabetic Individuals. In: International Symposium on Human Insulin, Eds Karam J H, Elzwiler D D, Diabetes Care; 6 (Suppl 1): 43-48.

NOVO INDUSTRI AS
Copenhagen, Denmark.

Further information is available on request from:
NOVO LABORATORIES LTD
Ringway House, Bell Road, Daneshill East, Basingstoke, Hampshire RG24 0QN.
Tel: Basingstoke (0256) 55055.

Novo Human Monocomponent Insulin for diabetic children with a full life ahead of them

whatever his mum worries about, it won't be his asthma.

Regular Intal therapy can give real protection from asthmatic attacks, minimising both incidence and severity.[1]

With reduced anxiety, there is less need to resort to symptomatic medication such as bronchodilators;[2] or oral corticosteroids.[3]

Current investigations suggest
that these improvements are accompanied by a reduction of cellular infiltration in bronchial mucus.[4]
Which indicates that Intal therapy may have a beneficial effect on the underlying pathology of asthma.

Because the Intal routine can be integrated unobtrusively into the day's normal activities, the asthmatic child can get on with the real business of growing up.

He'll be more at ease with his condition.
And so will his parents, teachers and friends.

References:

1. Bernstein, L. et al., *J.Allergy Clin.Immunol.*, (1972), **50**, 4, 235-245.
2. Rubin, A. E., Alroy, G. & Spitzer, S., *Curr.Med.Res.Opin.*, (1983), **8**, 553.
3. Toogood, J. H. et al., *J.Allergy Clin.Immunol.*, (1973), **52**, 6, 334-345.
4. Diaz, P. et al., *Thorax*. (1983), **38**, 9, 702-703.

Presentation Intal and Intal Compound Spincaps® both contain 20mg Sodium Cromoglycate B.P. Isoprenaline Sulphate (0.1mg) is included in Intal Compound Spincaps. The powder from Spincaps is inhaled using the Spinhaler® or Halermatic® which work by the patient's inspiratory effort. The Intal Inhaler is a metered dose pressurised aerosol delivering 200 inhalations of 1.0mg Sodium Cromoglycate. Intal Nebuliser Solution is presented in ampoules each containing 20mg Sodium Cromoglycate in 2ml sterile aqueous solution. **Indication** Preventive treatment of bronchial asthma, including the prevention of exercise-induced asthma. **Dosage and Administration** Adults and children: the normal dose is one Spincap (Intal or Intal Compound) two puffs of Inhaler or one ampoule of Nebuliser Solution to be inhaled four times daily. Intal Nebuliser Solution is administered from a suitable power-operated nebuliser. Since Intal therapy is preventive it is important that the patient is instructed to maintain regular dosage as distinct from intermittent use to relieve symptons. **Side effects** With the powder formulations of Intal, irritation of the throat and trachea may occur in patients sensitive to the inhalation of dry powder. Although it has not been reported for the Inhaler or Nebuliser Solution, rare cases of severe bronchospasm have occurred following the administration of Intal Spincaps using a Spinhaler. **Precautions** For Intal Compound the precautions normally applying to isoprenaline should be observed. **Withdrawal of therapy** This should be done progressively over one week. Symptoms may recur. Any previous steroid therapy should be reinstated prior to the withdrawal of Intal. **Basic NHS Cost and Product Licence Number** Intal (per 100 Spincaps) £10.07 PL0113/5022. Intal Compound (per 100 Spincaps) £8.19 PL0113/5023. Intal Inhaler (per 200 inhalations) £10.95 PL0113/0080. Nebuliser Solution (per 48 ampoules) £8.20 PL0113/0068. Fisons plc—Pharmaceutical Division, Loughborough, Leicestershire LE11 0BB. *Registered Trade Mark ©Fisons plc

FISONS Pharmaceuticals

Trust

Intal®

for firm control of asthma

SODIUM CROMOGLYCATE B.P.



ANNOUNCING A TRULY REMARKABLE CEPHALOSPORIN

PRESCRIBING INFORMATION OVERLEAF

NEW

FORTUM

ceftazidime

For the first time.

The bactericidal power of aminoglycosides and exceptional antipseudomonal activity from an extended spectrum cephalosporin.

Hospital antibiotics created in Britain by **Glaxo**

PRESCRIBING INFORMATION OVERLEAF

A new milk drink specially made for babies 4-6 months and older and nutritionally superior to cow's milk. That's Progress.

By the age of four months a baby's digestive system is maturing to cope with changing nutritional needs, such as extra protein intake.

Even when solids are introduced milk is still a very important source of nutrients.

Both the DHSS[1] and the European Society for Paediatric Gastroenterology and Nutrition (ESPGAN)[2] advise against the early introduction of doorstep cow's milk. In fact, it may be beneficial to avoid it for the first 12 months. ESPGAN have set out guidelines for and recommend the use of a follow-on formula rather than cow's milk.

PROGRESS is such a formula, for babies four to six months and older. Progress is not intended to replace breastfeeding. Given in conjunction with solids it provides more complete nutrition than cow's milk.

Boiling of cow's milk depletes vitamins such as B_1 and C and of course, diluting with water lowers all nutrients.

Parents will be pleased to know Progress contains a full complement of vitamins and minerals especially iron and vitamins A, C, D and E which are insufficient in cow's milk. The all vegetable fat blend contains a lot less saturated fat than cow's milk, with energy provided mainly from carbohydrate rather than fat.

Progress has 67% more carbohydrate than cow's milk and the high quality protein is readily usable for building of body tissue.

You will be pleased to know that Progress has been specially formulated for the older baby by Wyeth Nutrition, makers of Britain's most popular baby milk-food.



More suitable than cow's milk for older babies.

Wyeth Nutrition
Leading the way
*Trade marks

Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berks. SL6 0PH.

References 1. D.H.S.S. (1980) (Revised 1983) HMSO Report No. 20. Present Day Practice in Infant Feeding 5.2.1. **2.** ESPGAN Committee on Nutrition (1981) Guidelines on Infant Nutrition 11. Recommendations for the composition of follow up formula and Beikost. *Acta Paediatr Scand.*, Suppl. 287.



As a Consultant Paediatrician, you can look with confidence to the Cromwell Hospital for the ideal professional environment in which to treat the children under your care.

The hospital's paediatric unit comprises three four-bed suites with additional room provision for mother and child and, of course, a well equipped playroom staffed by nursery nurses.

This specialised unit is fully equipped for general paediatrics and all paediatric specialities including oncology.

In a separate but adjacent isolation area, the Bone Marrow Transplant Centre incorporates full facilities for transplantation.

All staff are highly trained in paediatric care and the unit has a full-time resident paediatrician.

We believe that Cromwell Hospital has the precise facilities you are seeking.

To arrange a personal visit and for further information contact Mr James Hempton, Professional Relations Manager.

London's Cromwell Hospital.
British healthcare at its best.

CROMWELL HOSPITAL

CROMWELL RD, LONDON SW5 0TU TEL: 01-370 4233 TELEX: 893589 CROHOS G

THE PROVEN ANSWER TO THE PRESENT DAY QUESTION...



REQUIREMENTS

EASILY DIGESTED WELL TOLERATED FORMULA. MEET HIGH NUTRIENT REQUIREMENT. ADAPTED TO MEET SPECIAL NEEDS. APPROPRIATE FOR AGA AND SGA BABIES. READY TO FEED. PURE AND STERILE TO PROTECT IMMATURE DIGESTIVE SYSTEM. SCREENED AGAINST HERBICIDES, PESTICIDES AND LEAD.

THE ANSWER IS:

PRE-APTAMIL (MEB) BY MILUPA. PROVEN BY OVER 10 YEARS SUCCESSFUL USE IN EUROPE AND BY UK CLINICAL TRIAL.[1]



Pre-Aptamil (MEB)

For further information contact Janet Souster BSc at Milupa Limited, Milupa House, Hobbs Hood, Hillingdon, Uxbridge, Middlesex UB10 9NA. Telephone: (0895) 59851

1 Brooke, O. G., Wood, C., Barley, J. *Arch. Dis. Child* 1982, **57**, 898–904.

European Journal of
Pediatrics

Incorporating
ACTA PAEDIATRICA BELGICA

Volume 142 Number 3 August 1984

Indexed in Current Contents

Subscription information: Volumes 142 and 143 (4 issues each) will appear in 1984. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: Approx. US $ 336.00 including carriage charges. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, USA, Tel. (201) 348-4033, Telex 0023-125994.

All other countries. Annual subscription rate: DM 820.00 plus carriage charges. Airmail delivery on request only. For *Japan*, carriage charges (Surface Airmail Lifted) are DM 71.50; for *India* DM 43.40. Single issue price: DM 123.00 plus carriage charges. Orders can either be placed with your bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33, Tel. (0)30/8207-1, Telex 01-83319.

Springer International

Monatsschrift Kinderheilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

132. Band
Heft 7
Juli 1984

Springer-Verlag
Berlin Heidelberg New York Tokyo

Indexed in Current Contents

Monatsschr Kinderheilkd (1984) 132, 7

Annual subscription: DM 232,– plus postage

PEDIATRIC RESEARCH

Volume 18, No. 6 June 1984

Contents

Tegretol®
carbamazepine BP

making epilepsy easier to live with

Tegretol®
Indications Epilepsy (generalised tonic-clonic and partial seizures), trigeminal neuralgia. Dosage in epilepsy Use a gradually increasing dosage scheme, adjusting to patient's needs. Adults: 100-200mg once or twice daily, increasing slowly up to 800-1,200mg daily; in some cases 1,600mg daily may be necessary. Children: up to 1 year old, 100-200mg daily; aged 1-5 years, 200-400mg daily; aged 5-10 years, 400-600mg daily; aged 10-15 years, 600-1,000mg daily. It may be helpful to monitor plasma drug levels: optimum therapeutic range is 3-10ug/ml (13-42 umols/l). Dosage in trigeminal neuralgia Begin with small doses, using 100mg tablets or syrup, and increase gradually until satisfactory therapeutic response is obtained; 200mg 3-4 times daily is generally sufficient to maintain pain-free state. Side-effects Dizziness and diplopia (usually dose-dependent), less frequently drowsiness, dry mouth, diarrhoea, nausea and vomiting. Generalised erythematous rash, disappearing on cessation of therapy. Isolated reports of oedema, hyponatraemia, exfoliative dermatitis, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment. Precautions Caution in patients taking oral anticoagulants or requiring oral contraception. In pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with, or within two weeks of cessation of, MAOI therapy. In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant bearing on the therapeutic use of the drug). Serum folic acid levels should be observed during anticonvulsant therapy. Contra-indications Previous drug sensitivity to Tegretol. Do not administer to patients with atrioventricular conduction abnormalities unless paced. Packs Tablets of 100mg (PL0001/5027) basic NHS price £2.90 per 100, £13.95 per 500; tablets of 200mg (PL0001/5028) £5.38 per 100, £25.93 per 500; tablets of 400mg (PL0001/0088) £10.58 per 100; syrup 100mg/5ml (PL0001/0050) £5.17 per 300ml bottle. ® denotes registered trademark. **Geigy**
Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.